Lung Cancer

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on How the Institutes in the mutlicenter study examining driver mutations Worked Together

Add-on therapy with an inhibitor of the MET signaling pathway significantly improved PFS and OS in patients with MET-positive NSCLC confirmed by immunohistochemistry.

Dr. Jack West from Swedish Cancer Institute Discusses 4 Important Upcoming Clinical Trials Results in Lung Cancer.

Amrubicin improved response rates, improved progression- free survival (PFS), and achieved enhanced symptom control with acceptable toxicity compared with topotecan.

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses the Field of Mutation Testing

Findings from a randomized phase III trial in China suggest erlotinib is suitable for first-line treatment in patients with EGFR mutation-positive NSCLC.

Oncologists need to prepare for a new era in which rapidly advancing genetic technology will change the way cancer is treated.

Dr. Jack West from Swedish Cancer Institute Explains the Pemetrexed Clinical Trial

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design

Dr. Mark G. Kris thoracic chair at Memorial Sloan-Kettering Cancer Center Discusses Driver Mutations Test False Negatives

Although once considered a promising drug for lung cancer and other tumor types, motesanib added to carboplatin/paclitaxel chemotherapy did not improve overall survival.

Dr. Jack West Swedish Cancer Institute on the Gefitinib Advanced non-small cell lung cancer Trial

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Will graphic images and stronger warnings decrease cigarette smoking?

Crizotinib demonstrated marked antitumor activity among patients with advanced ALK-positive non–small cell lung cancer.

Dr. Mark G. Kris from Memorial Sloan-Kettering on Integrating Driver Mutation Testing Study Results

Dr. H. Jack West from Swedish Cancer Institute discusses Afatinib and Cetuximab Combination in NSCLC

A recent study revealed that celecoxib (Celebrex), a COX-2 inhibitor, might be a successful lung cancer chemoprevention in former smokers.

Patients screened with low-dose helical computed tomography (CT) reduced their risk of dying of lung cancer by 20% compared with chest x-ray.

Dr. Mark Kris from MSKCC Describes the Genetic Mutation Screening Multicenter Study

Dr. H. Jack West from Swedish Cancer Institute Discusses ALK-NSCLC Crizotinib Survival Benefit

Dr. Kris from Memorial Sloan-Kettering Discusses Tests Available for Lung Cancer

Dr. Mark Kris from Memorial Sloan-Kettering Cancer Center Discusses the Pemetrexed Clincal Trial Results

Dr. Jack West from the Swedish Cancer Institute Discusses Crizotinib in ALK-NSCLC Trial Results

Internationally known experts will discuss the latest research in breast and lung cancers at 2 conferences that the Physicians' Education Resource (PER) is hosting in California in August.